286 related articles for article (PubMed ID: 35269846)
1. PD-1/PD-L1 Immuno-Mediated Therapy in NAFLD: Advantages and Obstacles in the Treatment of Advanced Disease.
Lombardi R; Piciotti R; Dongiovanni P; Meroni M; Fargion S; Fracanzani AL
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269846
[TBL] [Abstract][Full Text] [Related]
2. NASH limits anti-tumour surveillance in immunotherapy-treated HCC.
Pfister D; Núñez NG; Pinyol R; Govaere O; Pinter M; Szydlowska M; Gupta R; Qiu M; Deczkowska A; Weiner A; Müller F; Sinha A; Friebel E; Engleitner T; Lenggenhager D; Moncsek A; Heide D; Stirm K; Kosla J; Kotsiliti E; Leone V; Dudek M; Yousuf S; Inverso D; Singh I; Teijeiro A; Castet F; Montironi C; Haber PK; Tiniakos D; Bedossa P; Cockell S; Younes R; Vacca M; Marra F; Schattenberg JM; Allison M; Bugianesi E; Ratziu V; Pressiani T; D'Alessio A; Personeni N; Rimassa L; Daly AK; Scheiner B; Pomej K; Kirstein MM; Vogel A; Peck-Radosavljevic M; Hucke F; Finkelmeier F; Waidmann O; Trojan J; Schulze K; Wege H; Koch S; Weinmann A; Bueter M; Rössler F; Siebenhüner A; De Dosso S; Mallm JP; Umansky V; Jugold M; Luedde T; Schietinger A; Schirmacher P; Emu B; Augustin HG; Billeter A; Müller-Stich B; Kikuchi H; Duda DG; Kütting F; Waldschmidt DT; Ebert MP; Rahbari N; Mei HE; Schulz AR; Ringelhan M; Malek N; Spahn S; Bitzer M; Ruiz de Galarreta M; Lujambio A; Dufour JF; Marron TU; Kaseb A; Kudo M; Huang YH; Djouder N; Wolter K; Zender L; Marche PN; Decaens T; Pinato DJ; Rad R; Mertens JC; Weber A; Unger K; Meissner F; Roth S; Jilkova ZM; Claassen M; Anstee QM; Amit I; Knolle P; Becher B; Llovet JM; Heikenwalder M
Nature; 2021 Apr; 592(7854):450-456. PubMed ID: 33762733
[TBL] [Abstract][Full Text] [Related]
3. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
4. New insights into checkpoint inhibitor immunotherapy and its combined therapies in hepatocellular carcinoma: from mechanisms to clinical trials.
Jin H; Qin S; He J; Xiao J; Li Q; Mao Y; Zhao L
Int J Biol Sci; 2022; 18(7):2775-2794. PubMed ID: 35541908
[TBL] [Abstract][Full Text] [Related]
5. Spatial proteomics of immune microenvironment in nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
Li M; Wang L; Cong L; Wong CC; Zhang X; Chen H; Zeng T; Li B; Jia X; Huo J; Huang Y; Ren X; Peng S; Fu G; Xu L; Sung JJY; Kuang M; Li X; Yu J
Hepatology; 2024 Mar; 79(3):560-574. PubMed ID: 37733002
[TBL] [Abstract][Full Text] [Related]
6. Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives.
Mocan T; Sparchez Z; Craciun R; Bora CN; Leucuta DC
Clin Transl Oncol; 2019 Jun; 21(6):702-712. PubMed ID: 30387047
[TBL] [Abstract][Full Text] [Related]
7. Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody.
Liu G; Zhou W; Li X; Guo L; He T; Zhao J; Gong L
Front Immunol; 2021; 12():712351. PubMed ID: 34504494
[TBL] [Abstract][Full Text] [Related]
8. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
[TBL] [Abstract][Full Text] [Related]
9. Trim21 deficiency in mice increases HCC carcinogenesis in a NASH context and is associated with immune checkpoint upregulation.
Kara-Ali GH; Cano L; Dion S; Imerzoukene G; Hamon A; Simoes Eugénio M; Piquet-Pellorce C; Ghukasyan G; Samson M; Le Seyec J; Dimanche-Boitrel MT
Int J Cancer; 2024 Jun; 154(11):1999-2013. PubMed ID: 38308587
[TBL] [Abstract][Full Text] [Related]
10. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y
J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366
[TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials.
Kudo M
Oncology; 2017; 92 Suppl 1():50-62. PubMed ID: 28147363
[TBL] [Abstract][Full Text] [Related]
12. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma.
Liu Z; Lin Y; Zhang J; Zhang Y; Li Y; Liu Z; Li Q; Luo M; Liang R; Ye J
J Exp Clin Cancer Res; 2019 Nov; 38(1):447. PubMed ID: 31684985
[TBL] [Abstract][Full Text] [Related]
13. Anti-CD122 antibody restores specific CD8
Lacotte S; Slits F; Moeckli B; Peloso A; Koenig S; Tihy M; El Hajji S; Gex Q; Rubbia-Brandt L; Toso C
Oncoimmunology; 2023; 12(1):2184991. PubMed ID: 36891258
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for NAFLD and NAFLD-related hepatocellular carcinoma.
Jeong S; Shin WY; Oh YH
Front Endocrinol (Lausanne); 2023; 14():1150360. PubMed ID: 37020584
[TBL] [Abstract][Full Text] [Related]
15. Navigating through the PD-1/PDL-1 Landscape: A Systematic Review and Meta-Analysis of Clinical Outcomes in Hepatocellular Carcinoma and Their Influence on Immunotherapy and Tumor Microenvironment.
Ailia MJ; Heo J; Yoo SY
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047482
[TBL] [Abstract][Full Text] [Related]
16. Pathogenic Th17 cell-mediated liver fibrosis contributes to resistance to PD-L1 antibody immunotherapy in hepatocellular carcinoma.
Song M; Wang L; Jiang S; Liang J; Li W; Rao W; Du Q; Liu G; Meng H; Tang L; Li Z; Yang Y; Zhang L; Zhang B
Int Immunopharmacol; 2024 Mar; 129():111601. PubMed ID: 38350354
[TBL] [Abstract][Full Text] [Related]
17. Metformin treatment rescues CD8
Wabitsch S; McCallen JD; Kamenyeva O; Ruf B; McVey JC; Kabat J; Walz JS; Rotman Y; Bauer KC; Craig AJ; Pouzolles M; Phadke I; Catania V; Green BL; Fu C; Diggs LP; Heinrich B; Wang XW; Ma C; Greten TF
J Hepatol; 2022 Sep; 77(3):748-760. PubMed ID: 35378172
[TBL] [Abstract][Full Text] [Related]
18. Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti-Programmed Cell Death-1 in HCC.
Yi C; Chen L; Lin Z; Liu L; Shao W; Zhang R; Lin J; Zhang J; Zhu W; Jia H; Qin L; Lu L; Chen J
Hepatology; 2021 Nov; 74(5):2544-2560. PubMed ID: 34036623
[TBL] [Abstract][Full Text] [Related]
19. PD-L1-Mediated Immunosuppression in Hepatocellular Carcinoma: Relationship with Macrophages Infiltration and Inflammatory Response Activity.
Guo S; Wang X; Zhou H; Gao Y; Wang P; Zhi H; Sun Y; Zhang Y; Gan J; Xiao Y; Ning S
Biomolecules; 2022 Sep; 12(9):. PubMed ID: 36139065
[TBL] [Abstract][Full Text] [Related]
20. Role of immune responses in the development of NAFLD-associated liver cancer and prospects for therapeutic modulation.
Yahoo N; Dudek M; Knolle P; Heikenwälder M
J Hepatol; 2023 Aug; 79(2):538-551. PubMed ID: 36893854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
